Kymera Therapeutics (KYMR) Stock Price, Quote, News & History

Comments

Kymera Therapeutics Inc (KYMR) Stock Price, Quote, News & History

KYMRNASDAQ

Trade with Public

$85.40

0.470.55%

At close: Apr 2, 5:00 PM EST

$85.40

N/A

After Hours: 4:00 PM EST

OverviewNews Earnings Options Analyst Ratings Insider Trades Short Interest Stock Report

Key Statistics

Open

$82.78

Close

$85.40

Volume / Avg.

690.93K / 774.51K

Day Range

$82.67 - $85.65

52 Wk Range

19.45 - 103.00

Market Cap

$6.83B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

58

Short Interest

15.01%

Days to Cover

13.82

Recent Kymera Therapeutics Inc News

Kymera Stock Smashes 52-Week High As New Pill Crushes Eczema Markers

Kymera Therapeutics released positive clinical results for KT-621 for atopic dermatitis and other allergic diseases.

Vandana Singh

Gilead Bets On Kymera's CDK2 Molecular Glue Degrader For New Cancer Therapies

Kymera signs $750 million CDK2 drug deal with Gilead and earns $20 million from Sanofi as KT-485 advances toward clinical trials in inflammatory diseases.

Vandana Singh

Applied Digital And Riot Platforms Are Among Top 10 Mid-Cap Gainers Last Week (Jun 2-Jun 6): Are The Others In Your Portfolio?

Lekha Gupta

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-232.89M

Investing Cash Flow (TTM)

-521.06M

Financing Cash Flow (TTM)

990.71M

Free Cash Flow (TTM)

-234.34M

Capital Expenditure (TTM)

-1.45M

Net Change in Cash (TTM)

236.76M

Analyst Trends and Forecast

17

Dec 25

2

Jan

3

Feb

4

Mar

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.0

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$6.20B

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

183.07

PB Ratio (TTM)

4.39

Earnings Yield % (TTM)

-4.34%

Earnings Yield % (FWD)

-4.32%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$19.35

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-$1.49M

Total Cash

$357.01M

Debt to Equity

0.05

Issuance of Debt (TTM)

-$1.49M

Repayment of Debt (TTM)

-$1.49M

Key Statistics

Open

$82.78

Close

$85.40

Volume / Avg.

690.93K / 774.51K

Day Range

$82.67 - $85.65

52 Wk Range

19.45 - 103.00

Market Cap

$6.83B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

58

Short Interest

15.01%

Days to Cover

13.82

About

Sector

Health Care

Industry

Biotechnology

Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of differentiated medicines that address health problems and meaningfully improve patients' lives. I...

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy Kymera Therapeutics (KYMR) stock?

A

You can purchase shares of Kymera Therapeutics (NASDAQ:KYMR) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Kymera Therapeutics (KYMR) competitors?

A

Other companies in Kymera Therapeutics’s space includes: Cogent Biosciences Inc (NASDAQ:COGT), Celcuity Inc (NASDAQ:CELC), Centessa Pharmaceuticals PLC (NASDAQ:CNTA), Alkermes PLC (NASDAQ:ALKS) and Xenon Pharmaceuticals Inc (NASDAQ:XENE).

Q

What is the forecast, or price target, for Kymera Therapeutics (KYMR) stock?

A

Kymera Therapeutics has a consensus price target of $96.63.

Q

What is the current price for Kymera Therapeutics (KYMR)?

A

The stock price for Kymera Therapeutics (NASDAQ: KYMR) is $85.4 last updated April 2, 2026 at 4:00 PM EDT.

Q

Does Kymera Therapeutics (KYMR) pay a dividend?

A

There are no upcoming dividends for Kymera Therapeutics.

Q

When is Kymera Therapeutics (NASDAQ:KYMR) reporting earnings?

A

Kymera Therapeutics does not have any upcoming earnings scheduled.

Q

Is Kymera Therapeutics (KYMR) going to split?

A

There is no upcoming split for Kymera Therapeutics.

Q

What sector and industry does Kymera Therapeutics (KYMR) operate in?

A

Kymera Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

People Also Watch

Cogent Biosciences Inc

Centessa Pharmaceuticals PLC

Xenon Pharmaceuticals Inc

Protagonist Therapeutics Inc

Key Statistics

Open

$82.78

Close

$85.40

Volume / Avg.

690.93K / 774.51K

Day Range

$82.67 - $85.65

52 Wk Range

19.45 - 103.00

Market Cap

$6.83B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

58

Short Interest

15.01%

Days to Cover

13.82

Recent Kymera Therapeutics Inc News

Kymera Stock Smashes 52-Week High As New Pill Crushes Eczema Markers

Kymera Therapeutics released positive clinical results for KT-621 for atopic dermatitis and other allergic diseases.

Vandana Singh

Gilead Bets On Kymera's CDK2 Molecular Glue Degrader For New Cancer Therapies

Kymera signs $750 million CDK2 drug deal with Gilead and earns $20 million from Sanofi as KT-485 advances toward clinical trials in inflammatory diseases.

Vandana Singh

Applied Digital And Riot Platforms Are Among Top 10 Mid-Cap Gainers Last Week (Jun 2-Jun 6): Are The Others In Your Portfolio?

Lekha Gupta

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-232.89M

Investing Cash Flow (TTM)

-521.06M

Financing Cash Flow (TTM)

990.71M

Free Cash Flow (TTM)

-234.34M

Capital Expenditure (TTM)

-1.45M

Net Change in Cash (TTM)

236.76M

Analyst Trends and Forecast

17

Dec 25

2

Jan

3

Feb

4

Mar

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.0

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$6.20B

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

183.07

PB Ratio (TTM)

4.39

Earnings Yield % (TTM)

-4.34%

Earnings Yield % (FWD)

-4.32%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$19.35

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-$1.49M

Total Cash

$357.01M

Debt to Equity

0.05

Issuance of Debt (TTM)

-$1.49M

Repayment of Debt (TTM)

-$1.49M

Key Statistics

Open

$82.78

Close

$85.40

Volume / Avg.

690.93K / 774.51K

Day Range

$82.67 - $85.65

52 Wk Range

19.45 - 103.00

Market Cap

$6.83B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

58

Short Interest

15.01%

Days to Cover

13.82

About

Sector

Health Care

Industry

Biotechnology

Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of differentiated medicines that address health problems and meaningfully improve patients' lives. I...

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry